Fragile X Syndrome (FXS)
10
3
3
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
10.0%
1 terminated out of 10 trials
75.0%
-11.5% vs benchmark
0%
0 trials in Phase 3/4
67%
2 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (10)
Optical Imaging in X-linked Disorders.
Intensive Multimodal Neurorehabilitation Targeting Neuroplasticity in Pediatric Neurodevelopmental and Chromosomal Disorders
A Study to Investigate the Effects and Safety of SPG601 for the Treatment of Fragile X Syndrome in Male Participants
The Neurocognitive Bases of Trust in Intellectual Disability
Neural Biomarkers in Fragile X Syndrome
Group CBT in Adolescents With Fragile X Syndrome and in Adolescents With Autism Spectrum Disorder
A Study of OV101 in Individuals With Fragile X Syndrome
Novel Clinical Target in Fragile X Syndrome
Neuroimaging GABA Physiology in Fragile X Syndrome
Decisional Capacity and Informed Consent in Fragile X Syndrome